In this podcast episode, listen to myeloma experts Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer audience questions from a live CCO Webinar on available and emerging therapeutic strategies for patients with early and late relapsed/refractory multiple myeloma.
In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:
• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial
• Selecting therapy for a patient with lenalidomide-refractory disease at first relapse
• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms
• Key findings from the DREAMM2 trial on belantamab mafodotin
• Monitoring and management strategies for ocular toxicity with belantamab mafodotin
Presenters:
Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain
Paula Rodriguez-Otero, MD, PhD
Associate Professor
Consultant in Hematology
Department of Hematology, Clínica Universidad de Navarra
University of Navarra
Pamplona, Spain
Prof. Dr. med. Katja Weisel
Deputy Director
II. Medical Clinic and Polyclinic
Department of Oncology and Hematology
Department of Pneumology and Bone Marrow Transplantation
University Medical Center
Hamburg-Eppendorf
Hamburg, Germany
Content based on an online CME program supported by an educational grant from GlaxoSmithKline.
Link to full program, including associated downloadable slidesets: